QLT Announces Court Response to Motion to Dismiss and Removal of Case to Fed...(n sales of Visudyne(R) in the United Sta...),Health

Date:5/21/2009

n sales of Visudyne(R) in the United States and Canada, and (b) included a "most favored nations" clause that required QLT to increase that royalty rate if QLT entered into a license agreement with Massachusetts Eye and Ear Infirmary ("MEEI") for certain patent rights at a higher rate. As previously announced, MEEI was recently awarded a 3.01% royalty rate, on worldwide sales of Visudyne, in a highly contested legal action against QLT involving claims for unjust enrichment. MGH alleged that the "most favored nations" clause was triggered by the judgment on this jury verdict. QLT disagreed, and moved to dismiss all of MGH's claims, with prejudice. QLT intends to vigorously contest the claim remaining in this lawsuit.

About QLT

QLT Inc. is a global biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies. Our research and development efforts are focused on pharmaceutical products in the field of ophthalmology. In addition, we utilize three unique technology platforms, photodynamic therapy, Atrigel(R) and punctal plugs with drugs, to create products such as Visudyne(R) and Eligard(R) and future product opportunities. For more information, visit our web site at www.qltinc.com.

    QLT Plug Delivery, Inc. is a wholly-owned subsidiary of QLT Inc.
    Atrigel is a registered trademark of QLT USA, Inc.
    Visudyne is a registered trademark of Novartis AG.
    Eligard is a registered trademark of Sanofi-aventis.

QLT Inc. is listed on The NASDAQ Stock Market under the trading symbol "QLTI" and on The Toronto Stock Exchange under the trading symbol "QLT."

Certain statements contained in this press release, which are not historical facts, are forward-looking statements, as the term is defined in the Private Securities Litigation Reform Act of 1995. You can identify these forward-
'/>"/>

SOURCE QLT Inc. Copyright©2009 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3
Related medicine news :

1. Authentidate Holding Corp. Announces Results From Annual Meeting of Stockholders
2. Secretary Shinseki Announces $215 Million in Projects for Rural Veterans
3. Perot Systems Announces Special Financing Options for Stimulus Plan Healthcare Technology Upgrades
4. Medstrat Announces Integration of Echoes With MacPractices EMR
5. Medivation Announces Upcoming Presentation of New MDV3100 Data in Patients With Advanced Prostate Cancer at 45th American Society of Clinical Oncology Annual Meeting
6. Cord Blood America, Inc. Announces 2009 First Quarter Results
7. Universal Health Services, Inc. Announces Marc D. Miller Named President of Universal Health Services
8. Universal Health Services, Inc. Announces Dividend
9. TouchMark Announces New Sales Representative
10. Sagent Pharmaceuticals Announces Extension of Series A Financing
11. Covidien announces milestone placement in remote respiratory monitoring